Find Clinical Trial

A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT)


← Back
Study Phase

Phase 3

Therapeutic Area

Rheumatology

IndicationOsteoporosis
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

STRONTIUM RANELATE,
S012911

Active Substance CodeS012911
Protocol CodeCL3-12911-019
ISRCTN CodeISRCTN82719233


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility